Pyridostigmine for the Treatment of Constipation in Parkinson Disease
Phase 2
18+
1 site in VT
What this study is about
This Phase 2 study is testing Pyridostigmine Bromide in people with constipation.
Simplified from trial records by PatientMatch.
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Assignment is predetermined by the study protocol.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Antimyasthenic Agents (Cholinesterase Inhibitors)
injection
Secondary: Changes from Baseline to the End of Study Visit in Beck Depression Inventory-II (BDI-II), Changes from Baseline to the End of Study Visit in the Gastrointestinal Dysfunction Scale in Parkinson's Disease (GIDS-PD), Changes from Baseline to the End of Study Visit in the MDS-Sponsored Revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Parts I-IV, Number of adverse events and serious adverse events that occur during the trial
Neurology, Gastroenterology